Depression and Anxiety Trial, Recruiting NCT04556890 Sponsor: University of California, Los Angeles Condition: Depression and Anxiety
Back to Depression And Anxiety

Depression and Anxiety Trial, Recruiting

NCT04556890
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 75 years of age
  • People who speak English fluently, at a level sufficient to understand and answer study questions
  • People who are right-handed
  • People who have a confirmed diagnosis of moderate Major Depressive Disorder (a single or repeated episode), with a score of at least 17 on a standard depression rating scale called the HAM-D17
  • People whose depression has not responded to at least 2 different antidepressant medications, from at least 2 different medication types
  • People who have also tried at least 2 additional evidence-based treatments added on top of antidepressants (not including medications called benzodiazepines)
  • People who have completed a course of talk therapy (psychotherapy) that is recognised as effective for depression, at an appropriate frequency and length
  • People who have a confirmed diagnosis of Fibromyalgia (FM) or Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), with at least moderate pain, scoring 15 or more on a standard pain questionnaire called the McGill Pain Questionnaire
  • People whose pain has been present for at least 3 months before joining the study
  • People who are able and willing to attend all required study visits and follow the treatment schedule

Who may not be able to join:

  • People who are unable to give informed consent due to mental or legal incapacity
  • People who are pregnant
  • People who currently have active thoughts of suicide or a suicide plan
  • People who have previously received Transcranial Magnetic Stimulation (TMS) treatment
  • People who have an infection or poor skin condition on the scalp where the treatment device would be placed
  • People with an increased risk of seizures, due to family history, a previous stroke, or current use of medications that raise seizure risk
  • People experiencing psychotic depression or other psychotic conditions (such as schizophrenia or related disorders) during their current depressive episode
  • People with neurological conditions such as epilepsy, stroke-related brain disease, dementia, increased pressure in the brain, a history of repeated or severe head injuries, or tumours in the brain or nervous system
  • People who have certain metal or magnetic devices implanted in their body, such as a cochlear implant, pacemaker, defibrillator, infusion pump, vagus nerve stimulator, aneurysm clips or coils, metal prostheses, staples, or stents (note: standard dental fillings are considered acceptable — confirm with trial site if unsure about a specific device)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 310-825-7797

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 March 2023
Est. completion
30 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Percent change in depression scores; Percent change in pain score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov